The total and l-tartrate labile acid phosphatase were studied in 25 patients with carcinoma of prostate. The results were compared with the results from a control group. Serum acid phosphatase levels both in the control groups and in patients with prostatic cancer were lower than bone marrow acid phosphatase levels. This may be due to acid phosphatase released from blood cells during hemolysis. A positive correlation between serum and bone marrow acid phosphatase levels in patients with prostatic carcinoma was found. There was a significant rise in bone marrow acid phosphatase levels (above the normal range from the control group) in patients with advanced stage III and stage IV prostatic carcinoma with significantly increased serum levels. The levels of bone marrow acid phosphatase gave a supplementary diagnostic method in the diagnosis of prostatic carcinoma. A hypothesis that raised levels of bone marrow acid phosphatase are diagnostic of early metastasis from prostatic carcinoma is given.

Keywords:
Prostatic carcinoma, Acid phosphatase, Early diagnosis
This content is only available via PDF.
© 1979 S. Karger AG, Basel
1979
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.